153 related articles for article (PubMed ID: 30278324)
1. Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV.
Kratzer A; Schießer S; Matzneller P; Wulkersdorfer B; Zeitlinger M; Schlossmann J; Kees F; Dorn C
J Pharm Biomed Anal; 2019 Jan; 163():34-38. PubMed ID: 30278324
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
[TBL] [Abstract][Full Text] [Related]
3. Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma.
Ezquer-Garin C; Ferriols-Lisart R; Alós-Almiñana M; Aguilar-Aguilar G; Belda-Nacher JF; Carbonell JA
Bioanalysis; 2018 Apr; 10(7):461-473. PubMed ID: 29633862
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine.
Putnam WC; Kallem RR; Edpuganti V; Subramaniyan I; Hall RG
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122354. PubMed ID: 32905989
[TBL] [Abstract][Full Text] [Related]
7. Measurement of ceftolozane and tazobactam concentrations in plasma by UHPLC-MS/MS. Clinical application in the management of difficult-to-treat osteoarticular infections.
Rigo-Bonnin R; Gomez-Junyent J; García-Tejada L; Benavent E; Soldevila L; Tubau F; Murillo O
Clin Chim Acta; 2019 Jan; 488():50-60. PubMed ID: 30385280
[TBL] [Abstract][Full Text] [Related]
8. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
[TBL] [Abstract][Full Text] [Related]
9. Determination of total or free cefazolin and metronidazole in human plasma or interstitial fluid by HPLC-UV for pharmacokinetic studies in man.
Dorn C; Kratzer A; Schießer S; Kees F; Wrigge H; Simon P
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1118-1119():51-54. PubMed ID: 31005774
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study.
Yu B; Adedoyin A; Hershberger E; Caro L; Xiao A; Rhee EG; Huntington JA
Clin Pharmacol Drug Dev; 2018 May; 7(4):382-391. PubMed ID: 29517862
[TBL] [Abstract][Full Text] [Related]
11. Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study.
Al Jalali V; Wölfl-Duchek M; Taubert M; Matzneller P; Lackner E; Dorn C; Kratzer A; Wulkersdorfer B; Österreicher Z; Zeitlinger M
J Antimicrob Chemother; 2021 Aug; 76(9):2342-2351. PubMed ID: 34050650
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
Bradley JS; Ang JY; Arrieta AC; Larson KB; Rizk ML; Caro L; Yang S; Yu B; Johnson MG; Rhee EG
Pediatr Infect Dis J; 2018 Nov; 37(11):1130-1136. PubMed ID: 30153232
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
[TBL] [Abstract][Full Text] [Related]
15. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Melchers MJ; Mavridou E; Seyedmousavi S; van Mil AC; Lagarde C; Mouton JW
Antimicrob Agents Chemother; 2015; 59(6):3373-6. PubMed ID: 25824214
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
Rawlins M; Cheng V; Raby E; Dyer J; Regli A; Ingram P; McWhinney BC; Ungerer JPJ; Roberts JA
Chemotherapy; 2018; 63(4):203-206. PubMed ID: 30304718
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane-tazobactam: A new-generation cephalosporin.
Cluck D; Lewis P; Stayer B; Spivey J; Moorman J
Am J Health Syst Pharm; 2015 Dec; 72(24):2135-46. PubMed ID: 26637512
[TBL] [Abstract][Full Text] [Related]
18. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G
J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
